title: [Mortality of patients with ST-elevation acute myocardial infarction treated with primary angioplasty or thrombolysis].
abstract: BACKGROUND
  Primary angioplasty is the most effective treatment of ST-segment elevation acute myocardial infarction (STEMI). However, its worldwide implementation is difficult to obtain. Therefore thrombolysis continues to be the treatment most commonly used.
  
  
  OBJECTIVE
  To evaluate in-hospital and long term mortality of patients with STEMI treated with thrombolysis or angioplasty, in three hospitals participating in the Chilean National Registry of Acute MI (GEMI group).
  
  
  METHODS
  Registry of 1,634 consecutive patients with STEMI admitted between 2002 and 2006. Risk was stratified using the Thrombolysis in Myocardial Infarction (TIMI) Risk Score. Hospital and log term mortalities were adjusted using logistic and Cox regression models.
  
  
  RESULTS
  Fifty nine percent of patients (967 patients aged 60+/-12 years, 77% males) were subjected to reperfusion therapies, 28% with primary angioplasty and 72% with thrombolysis. Hospital mortality rates among patients treated with thrombolysis and angioplasty were 10.9% and 5.6% (p =0.01), respectively The figures for long term mortality were 20.4% and 9.7%, respectively (p <0.01). Multivariate analysis confirmed the lower mortality among subjects treated with angioplasty, with an odds ratio (OR) in favor of angioplasty of 8.5 (95% confidence intervals (CI) 3-35) for in hospital mortality and of 4.7 (95% CI 2.6-8.3) for long term mortality. The higher benefits of angioplasty were observed in males, in the elderly and in patients with a TIMI score over >3.
  
  
  CONCLUSIONS
  Hospital and long term mortality of patients with STEMI was lower among those treated with primary angioplasty. This treatment is most beneficial among males, in the elderly and in patients with a TIMI score >3 .
authors.affiliation: Departamento de Enfermedades Cardiovasculares, Pontificia Universidad Católica de Chile, Santiago, Chile.
authors.forename: Douglas
authors.initials: D
authors.lastname: Greig
authors.forename: Ramón
authors.initials: R
authors.lastname: Corbalán
authors.forename: Pablo
authors.initials: P
authors.lastname: Castro
authors.forename: Pabla
authors.initials: P
authors.lastname: Campos
authors.forename: Rubén
authors.initials: R
authors.lastname: Lamich
authors.forename: Patricio
authors.initials: P
authors.lastname: Yovaniniz
mesh_terms: D000328:Adult; D017677:Age Distribution; D000368:Aged; D017130:Angioplasty; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D017052:Hospital Mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000401:mortality* / Q000628:therapy; D015425:Myocardial Reperfusion / Q000379:methods*; D011446:Prospective Studies; D016019:Survival Analysis; D015996:Survival Rate; D015912:Thrombolytic Therapy; D013997:Time Factors
chemical_list: D005343:Fibrinolytic Agents